BuruliVac
Identification and development of vaccine candidates for Buruli Ulcer Disease
- Description
BuruliVac aims at identifying and developing novel vaccine candidates against M. ulcerans, a bacterium causing Buruli Ulcer Disease (BUD), the third most common mycobacterial disease in immunocompetent humans. BUD is a necrotising disease of the skin that produces massive ulcers and permanent disabling scars. A vaccine against M. ulcerans would protect persons at risk in highly endemic areas and could be used as a therapeutic vaccine to shorten duration of treatment and to prevent relapses.
- Coordinator
- Prof. Bernhard FleischerEmail
- Programme
- FP7
- Duration
- 39 months (March 2010 - May 2013)
- Project funding
- € 4,599,983.00
- Project partners
- 16